Champions Oncology, Inc. (Nasdaq:CSBR), a translational oncology research organization, announced its financial results for the fiscal year and fourth quarter ending April 30, 2025. The company reported record annual revenue of $57 million, marking a 14% increase year-over-year. Net income for the fiscal year was $4.6 million, and adjusted EBITDA income reached $7.1 million. Total oncology revenue for fiscal year 2025 was $56.9 million, up from $50.2 million in the previous year, attributed to a 4% growth in research services and $4.7 million from data license revenue. Operating expenses decreased by 9% to $52.4 million for fiscal year 2025. For the fourth quarter, total revenue was $12.3 million, with a reported adjusted EBITDA loss of $1.2 million. Total oncology revenue for the fourth quarter was $12.4 million, representing a 12% decrease from the previous year's $14.0 million, but aligning with expectations. Operating cash flow for the quarter was $6.4 million, and new data licensing revenue contributed approximately $200,000. David Miller, CFO of Champions, highlighted the company's fiscal 2025 financial turnaround, driven by disciplined execution and operational efficiency, leading to record adjusted EBITDA and a strengthened balance sheet. The company expresses confidence in building upon this momentum in fiscal 2026. Full financial details will be available in the Company's Form 10-K by July 29, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1051931) on July 23, 2025, and is solely responsible for the information contained therein.
Comments